Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$2.48M
68.59K shares · 0.0% of portfolio
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc (COLL) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Stoughton, United States and has 423 employees. The company is worth $765.06M and trades at 18.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $780.57M in fiscal 2025, up 23.6% from the year before. Net income was $62.87M. The share price is 53.7% below its 52-week high of $50.79. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $49.47M. In that quarter, 2 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +31.9% over 5Y.
today you would have $1,181.36▲ +18.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $46.30 | $28.65 | $30.78 | $23.20 | $18.68 | $20.03 | $20.58 | $17.17 | $18.46 | $15.57 | $27.50 | |
| P/E | 23.9x | 26.8x | 15.4x | 23.9x | — | 10.0x | 26.4x | — | — | — | — | — |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 17.9% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 23.9 across this company’s own years on record.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HELPHelus Pharma Inc. | $10.55 | — | 2.7x | 0.00% | -86.94% | $770.78M |
| VREXVarex Imaging Corp | $18.41 | 34.7x | 1.6x | 0.00% | 4.59% | $781.75M |
| PHRPhreesia, Inc. | $12.72 | 70.7x | 2.1x | 0.00% | 3.12% | $789.54M |
| APMDApnimed, Inc. | $17.76 |
| P/S | 2.1x | 1.9x | 1.4x | 1.7x | 1.7x | 2.3x | 2.2x | 2.4x | 2.0x | 21.4x | 268.0x | — |
| P/B | 4.9x | 4.9x | 3.9x | 5.0x | 4.1x | 3.1x | 3.7x | 8.0x | 6.2x | 5.9x | 3.4x | 7.6x |
| EPS | $1.73 | $1.86 | $1.29 | -$0.74 | $1.86 | $0.76 | -$0.68 | -$1.19 | -$2.47 | -$3.88 | -$1.48 |
| Profit margin | 1.33% | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% | 8.63% | -7.66% | -13.95% | -262.91% | -5504.15% | — |
| ROE | -12.83% | 20.84% | 30.23% | 24.64% | -12.83% | 35.24% | 14.38% | -25.99% | -42.72% | -71.93% | -69.81% | -32.04% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 2 families.
Room for errors in the reported numbers.
+89.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 2.5x |
| — |
| 0.00% |
| — |
| $739.36M |
| ALMSAlumis Inc | $6.12 | — | 1.7x | 0.00% | -93.65% | $792.14M |
| SGPSpyGlass Pharma, Inc. | $24.00 | — | 3.5x | 0.00% | — | $802.75M |